폐경 후 골다공증 및 골감소증 여성의 denosumab 약물 사용 평가
Medication Use Evaluation of Denosumab in Postmenopausal Women with Osteoporosis or Osteopenia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX). Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1st, 2017 to January 31st, 2020. Risk factors were identified using quantitative Ngram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (Tscore), was obtained from electronic medical records. Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy. Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.
Abstract
Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX). Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1st, 2017 to January 31st, 2020. Risk factors were identified using quantitative Ngram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (Tscore), was obtained from electronic medical records. Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy. Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.
참고문헌 (15)
- Kanis, JA, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Who Study Group", Osteoporos Int, 4(6), pp.368~381 (1994)
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, "Osteoporosis prevention, diagnosis, and therapy", JAMA, 285(6), pp.785~795 (2001)
- Yun HG, "Physician's guide for osteoporosis 2018", pp.12~90 (2018), Korean society for bone and mineral research
- Heaney RP, "Peak bone mass", Osteoporos Int, 11(12), pp.985~1009 (2000)
- Kim JC, "Bone mineral density of Korean women and comparison of bone mineral density in pre-and postmenopausal women", Korean J Obstet Gynecol, 39(10), pp.1905~1912 (1996)
- Riggs BL, "Sex steroids and the construction and conservation of the adult skeleton", Endocr Rev, 23(3), pp.279~302 (2002)
- Lash RW, "Diagnosis and management of osteoporosis", Prim Care, 36(1), pp.181~198 (2009)
- "FRAX"[URL]
- Camacho PM, "American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016", Endocr Pract, 22(Suppl 4), pp.1~42 (2016)
- "Institutional Statute: insurance recognition standards July 2020"[URL]
- Eastell R, "Pharmacological management of osteoporosis in postmenopausal women : An endocrine society clinical practice guideline", J Clin Endocrinol Metab, 104(5), pp.1595~1622 (2019)
- Cavnar W.B., "N-gram-based text categorization ngram-based text categorization", Proc. Third Annu. Symp. Doc. Anal. Inf. Retr, pp.1~14 (2001)
- Papapoulos S, "The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis : results from the FREEDOM extension study", Osteoporos Int, 26(12), pp.2773~2783 (2015)
- 고정민, "Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension", Yonsei Medical Journal, 57(4), pp.905~914 (2016), 연세대학교의과대학[DOI]
- Nakamura T, "Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis", Osteoporos Int, 23(3), pp.1131~1140 (2012)